United States Patent [19]

Michaeli

[11] **Patent Number: 4,745,098**

[45] **Date of Patent: May 17, 1988**

[54] **COMPOSITIONS AND METHOD FOR IMPROVING WOUND HEALING**

[75] Inventor: **Dov Michaeli**, San Francisco, Calif.

[73] Assignee: **The Regents of the University of California**, Berkeley, Calif.

[21] Appl. No.: **583,159**

[22] Filed: **Feb. 24, 1984**

[51] **Int. Cl.**[4] **A61K 37/00**; A61K 31/725; A61K 31/715

[52] **U.S. Cl.** **514/2**; 514/56; 514/54; 514/822

[58] **Field of Search** 424/177, 183; 536/21; 514/54, 56, 2

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,060,081	11/1977	Yannas et al.	128/156
4,350,629	9/1982	Yannas et al.	260/123.7
4,418,691	12/1983	Yannas et al.	128/156
4,448,718	5/1984	Yannas et al.	260/123.7

FOREIGN PATENT DOCUMENTS

6652	1/1969	France .
2362632	3/1978	France .
1205609	9/1970	United Kingdom .

OTHER PUBLICATIONS

Yannas et al., Stage 2 Artificial Skin: A Polymeric Template for Regeneration of New Skin, Chem Abstracts 99: 110713m (1982).

Danielsen, Mechanical Properties of Reconstituted Collagenfibrils, Influence of a Glycosaminoglycan: Dermatan Sulfate, Chem Abstracts 98:1845q (1982).

Yannas et al., Design Principles and Preliminary Clinical Performance of an Artificial Skin, Chem Abstracts 97: 115299z (1982).

Jungneira et al., Correlation of Specific Sulfated Glycosaminoglycans with Collagen Types I, II and III, Chem Abstracts 95:21810r (1981).

Gallagher et al., Synthesis of Glycosaminoglycans by Human Skin Fibroblasts Cultured on Collagen Gels, Chem Abstracts 93: 235868y (1980).

Dagalakis et al., Design of an Artificial Skin, Part III, Control of Pore Structure, Chem Abstracts 93: 225595t (1980).

Stryer: Biochemistry (2nd ed.), pp. 200–203 (1981).

Nature 297:307, 1982; S. Taylor et al., "Protamine is an Inhibitor of Angiogenesis".

Science 721:719, 1983; J. Folkman et al., "Angiogenesis Inhibition Caused by Heparin in the Presence of Cortisone".

Journ. of Biomed. Materials Research 14:511 1980—N. Dagalakis et al., "Design of an Artificial Skin".

Technology Review–May/Jun. 1981; pp. 79–81.

Ann. Surgery 194:413 1981; J. Burke et al.

Journ. of Biomed. Materials Research 14:107–1980, I. Yannas et al.

Journ. of Biomed. Materials Research 14:65—1980; I. Yannas et al.

Cancer Research 43:1790—1983—G. Alessandri et al.

J. Clinical Investigations 62:916 et seq. 1978 T. M. Chiang et al.

Primary Examiner—J. R. Brown
Assistant Examiner—John W. Rollins
Attorney, Agent, or Firm—Phillips, Moore, Lempio & Finley

[57] **ABSTRACT**

The healing of wounds is promoted by contacting the wound surfaces with a suspension of collagen and a glycosaminoglycan that is chemotactic for fibroblasts and/or endothelial cells. Typical glycosaminoglycans that exhibit the desired chemotaxis are heparin, heparan sulfate, and alginate. Two or more glycosaminoglycans can be present in the suspensions. Collagen is present in the suspension in the order of 7–10 mg/ml; while the glycosaminoglycan is present in much lower concentrations, e.g., 250–350 μg/ml. Application of the collagen/glycosaminoglycan suspension to open wounds greatly increases the rate of healing.

46 Claims, No Drawings